奥精医疗(688613) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥47,360,874.94, representing a decrease of 0.94% compared to the same period last year [4] - The net profit attributable to shareholders decreased by 62.52% to ¥6,938,107.45, primarily due to the accrual of share-based payment expenses [8] - Basic and diluted earnings per share were both ¥0.052, reflecting a decrease of 62.86% compared to the previous year [5] - Net profit for Q1 2024 was CNY 5,389,244.56, down 67.8% from CNY 16,771,370.97 in Q1 2023 [18] - Earnings per share (EPS) for Q1 2024 was CNY 0.05, compared to CNY 0.14 in Q1 2023 [19] Cash Flow - The net cash flow from operating activities was negative at -¥2,090,216.95, a decline of 116.78% attributed to increased R&D expenses and delayed sales revenue collection [5] - Cash flow from operating activities showed a net outflow of CNY 2,090,216.95, a decline from a net inflow of CNY 12,458,006.69 in Q1 2023 [22] - Net cash flow from financing activities was -$1,981,194.18 for Q1 2024, compared to -$6,193,364.62 in the same period last year [23] - Cash dividends and interest payments totaled $681,194.18 in Q1 2024, down from $893,364.62 in Q1 2023 [23] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,520,537,575.64, a slight decrease of 0.37% from the end of the previous year [5] - The total current assets were reported at ¥1,200,374,680.67, slightly decreasing from ¥1,200,748,124.98 at the end of 2023 [14] - The total liabilities decreased to ¥104,664,745.71 from ¥122,611,593.85, indicating a reduction of about 14.6% [15] - The company's total assets amounted to CNY 1,520,537,575.64, slightly down from CNY 1,526,256,853.43 at the end of the previous quarter [16] Research and Development - R&D investment totaled ¥7,554,567.39, accounting for 15.95% of operating revenue, an increase of 3.45 percentage points year-on-year [5] - Research and development expenses increased to CNY 7,554,567.39, up 26.4% from CNY 5,978,004.80 in Q1 2023 [17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,732 [10] - The largest shareholder, HU ERIC GANG, holds 9,487,066 shares, representing 7.12% of the total shares [10] Inventory and Accounts - The company's inventory decreased to ¥27,672,219.39 from ¥32,704,015.74, a decline of approximately 15.5% [14] - The company's accounts receivable increased to ¥76,259,788.13 from ¥59,270,254.21, reflecting a growth of approximately 28.7% [13] - The company reported a significant reduction in accounts payable from ¥10,387,177.69 to ¥5,840,988.74, a decrease of approximately 43.5% [15] Other Financial Metrics - The weighted average return on net assets was 0.50%, down by 0.98 percentage points year-on-year [5] - The company reported non-recurring gains of ¥3,505,393.55, primarily from government subsidies and other financial activities [6] - Management expenses rose sharply to CNY 18,169,296.39, compared to CNY 8,691,023.95 in the previous year, reflecting a 108.5% increase [17] - The company's capital reserve increased to ¥934,135,434.04 from ¥926,924,889.61, reflecting a growth of about 0.1% [15] Market Activity - The company has not reported any new product launches or significant market expansion strategies during this quarter [12]